Health-related quality of life and cost-effectiveness of gastric plication in the treatment of morbid obesity
| Date | Volume | Issue | Start Page | End Page |
|---|---|---|---|---|
2023-07-28 | 33 | S2 | 692 | 692 |
E-poster no. P-167
Background Laparoscopic gastric greater curvature plication (LGGCP) is a novel bariatric procedure. It is unknown if LGCCP is a cost-effective strategy for treating patients with morbid obesity. The aim of this study was to assess weight loss, health-related quality of life, and cost-effectiveness of LGGCP in treating individuals with morbid obesity. Methods Between April 2017 and December 2018, 112 patients were included in this study. Fifty patients had LGGCP, and sixty-two patients underwent laparoscopic Roux-en-Y gastric bypass (LRYGB). Demographics, weight loss and health-related quality of life were analyzed. This study performed a real-world cost-effectiveness analysis of LGGCP versus LRYGB, estimating the incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY). The analysis was done from the perspective of the Lithuanian National Insurance Fund, a public body responsible for healthcare coverage in Lithuania. The designed Markov model. Results The average operation time was similar in the LGGCP and LRYGB groups, with 78.20 (16.56) and 74.92 (15.85) minutes. The mean %EBMIL 1 year after surgery was 59.05 (25.34) in the LGGCP group and 82.40 (19.03) in the LRYGB group (P < 0.001) and 3 years after was 41.44 (26.74) and 75.59 (19.14), respectively (P < 0.001). After surgery, the quality of life of both groups improved statistically significantly. There was no difference in HRQoL between groups in one year (P = 0.247), but in three years after surgery, it was significantly better in the LRYGB group (P < 0.001). The undiscounted and discounted life expectancy was increased in the LRYGB group as compared to the LGGCP treatment arm (0.88 LY and 0.28 LY, respectively). The estimated lifetime costs (EUR 2020) were lower by 555.25 euros in the LRYGB group. LRYGB was dominant (less costly and more effective) than LGGCP when the incremental-cost effectiveness ratio was estimated. LRYGB was the dominant treatment option in 85.2 % of iterations, and the rest 14.8 % were not willing to pay more than 610 euros /QALY. Conclusions LGGCP patients lost significantly less weight and had a lower quality of life than LRYGB patients. LGGCP was more costly and less effective than LRYGB in treating individuals with obesity.